Stragen
Sonia Zanardi is a seasoned professional in the pharmaceutical industry with extensive experience in quality assurance and regulatory affairs. Currently serving as Pharmacien Responsable at Stragen since January 2021, Sonia is responsible for the implementation of quality management systems and management of third parties. Previously, Sonia held the position of Quality Assurance Manager at Recipharm from December 2008 to December 2020, where the establishment and maintenance of the site quality system and management of the Operational Quality Assurance staff were key responsibilities. In earlier roles, Sonia worked as a Quality Assurance Pharmacist at LFB, certifying sterile injectable products, a Pharmaceutical Affairs Pharmacist at Pfizer overseeing corporate pharmaceutical activities across Europe, and in Regulatory and Pharmaceutical Affairs at Sanofi, focusing on the preparation and updating of regulatory files. Sonia holds degrees in Pharmacy from Alma Mater Studiorum – Università di Bologna and in Industrial Pharmacy from Università degli Studi di Bologna.
This person is not in the org chart
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.